Our CSO Shin-Il Kim, along with Peter Karagiannis at Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan, published an article "iPSC-Derived Natural Killer Cells for Cancer Immunotherapy" in Molecules and Cells (IF: 4.250). 

This review describes the importance and future vision of Therabest’s main focus, iPSC (induced Pluripotent Stem Cells)-derived NK cells in cancer immunotherapy.

Please refer to the following link.

https://www.molcells.org/journal/view.html?pn=mostread&uid=4317&vmd=Full